Karolinska Institutet is one of the world´s leading medical universities, accounting for over 40 per cent of the medical academic research conducted in Sweden, and offers the country´s broadest range of education in medicine and health sciences.
The Affinomics laboratory was a former node of the Structural Genomics Consortium (2005-2011), working with 450 human protein targets from cloning to protein purification and crystallography. This work resulted in over 170 crystal structures of human proteins released in Protein Data Bank accompanied by many publications. Karolinska Institute became an independent partner of Affinomics in the FP7 programme in April 2011. The Affinomics work at KI is lead by Dr. Tomas Nyman.
Role in AFFINOMICS: The aim is to provide soluble proteins in milligram amounts of all 120 human SH2 domains (WP1), in both biotinylated and non-biotinylated form and distribute purified protein to binder producing groups within Affinomics. Additionally, domains from around 50 proteins of cancer related families will be produced in the same way.